May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intraocular Pressure Elevation After the Injection of Triamcinolone Acetonide: A Retrospective Multicenter Study
Author Affiliations & Notes
  • M. Inatani
    Dept of Ophthalmol & Vis Sci, Kumamoto Univ Grad Sch of Med Sci, Kumamoto, Japan
  • K. Iwao
    Dept of Ophthalmol & Vis Sci, Kumamoto Univ Grad Sch of Med Sci, Kumamoto, Japan
  • Y. Hirano
    Dept of Ophthalmol & Vis Sci, Nagoya City Univ Grad Sch of Med Sci, Nagoya, Japan
  • K. Hirooka
    Department of Ophthalmology, Kagawa University Faculty of Medicine, Kagawa, Japan
  • Y. Nakanishi
    Division of Ophthalmology, Kobe Univ Grad Sch of Med, Kobe, Japan
  • Y. Shimonagano
    Department of Ophthalmology, Kagoshima Univ Grad Sch of Med & Dent Sci, Kagoshima, Japan
  • C. Shima
    Department of Ophthalmology, Kansai Medical University, Osaka, Japan
  • Triamcinolone Acetonide Study Group
    Dept of Ophthalmol & Vis Sci, Kumamoto Univ Grad Sch of Med Sci, Kumamoto, Japan
  • Footnotes
    Commercial Relationships M. Inatani, None; K. Iwao, None; Y. Hirano, None; K. Hirooka, None; Y. Nakanishi, None; Y. Shimonagano, None; C. Shima, None.
  • Footnotes
    Support Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan, and from the Ministry of Health and Welfare, Japan.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 256. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Inatani, K. Iwao, Y. Hirano, K. Hirooka, Y. Nakanishi, Y. Shimonagano, C. Shima, Triamcinolone Acetonide Study Group; Intraocular Pressure Elevation After the Injection of Triamcinolone Acetonide: A Retrospective Multicenter Study. Invest. Ophthalmol. Vis. Sci. 2007;48(13):256.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To investigate frequency for the intraocular pressure (IOP) elevation after sub-Tenon capsule injection (STI) and intravitreal injection (IVI) of triamcinolone acetonide.

Methods:: The study included 406 eyes of 406 patients receiving either STI or IVI of triamcinolone acetonide at six clinical centers between May 2002 and September 2005. Patients with other corticosteroid administration, uveitis, ocular hypertension or glaucoma were excluded in this retrospective study. The IOP levels had been followed at least for 6 months after the administration of triamcinolone acetonide.

Results:: IOP levels of 24 mmHg or higher were observed in 14.3% of eyes treated with 40 mg STI while the IOP elevation was observed in only 3.7% of eyes with 20 mg STI, demonstrating significantly higher frequency for IOP elevation in 40 mg STI (p = 0.00074; chi-square test). Four mg and 8 mg IVIs induced the elevated IOP levels in the frequency of 5.6% and 38.5%, respectively, which also showed statistically significant difference (p = 0.010; chi-square test). The combination of STI and IVI induced the IOP elevation in 26.8%. Moreover, additional triamcinolone acetonide was administered in 135 of 406 eyes, of which 129 eyes had not encountered elevated IOP levels of 24 mmHg or higher in the first administration. But, among the 129 eyes, second administration induced elevated IOP levels of 24 mmHg or higher in 5.2% in 20 mg STI, 20.5% in 40 mg STI, 27.3% in 4 mg IVI, 36.4% in 8 mg IVI and 60.0% in STI plus IVI.

Conclusions:: The frequency for IOP elevation after the injection of triamcinolone acetonide shows dose-dependency. Second injection induces IOP elevation in eyes that had never shown IOP elevation in the first injection. IOP levels should be carefully monitored in eyes treated with the repeated or high dose administration.

Keywords: corticosteroids • intraocular pressure • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×